Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Tempe, Arizona Clinical Trials

A listing of Tempe, Arizona clinical trials actively recruiting patient volunteers.

RESULTS

Found (25) clinical trials

Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

At this time, there is no standard medical treatment for MF-BP or MF-AP. The investigators believe that the combination of ruxolitinib and DEC is a candidate approach to the treatment of MF-BP/MF-AP that is worthy of exploration based on both the current understanding of the biology of disease and emerging ...

Phase

3.57 miles

Learn More »

Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma

X4P-001 is an orally bioavailable CXCR4 antagonist that has demonstrated activity in various tumor models. CXCR4 (C-X-C chemokine receptor type 4) is the receptor for CXCL12 (C-X-C chemokine ligand type 12). CXCL12 has potent chemotactic activity for lymphocytes and MDSCs (myeloid-derived suppressor cells), and is important in homing of hematopoietic ...

Phase

4.81 miles

Learn More »

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK) **Please note that the study is no longer enrolling patients for Groups A, B, C, and E.

Phase

7.43 miles

Learn More »

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

This is a two-part study of pembrolizumab (MK-3475) in pediatric participants who have any of the following types of cancer: advanced melanoma (6 months to <18 years of age), advanced, relapsed or refractory programmed death-ligand 1 (PD-L1)-positive malignant solid tumor or other lymphoma (6 months to <18 years of age), ...

Phase

7.43 miles

Learn More »

A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated

This is an open-label, nonrandomized, multicenter Phase 1/2 study of MEDI4736 in subjects with recurrent, platinum-resistant ovarian cancer, scheduled to receive Pegylated Liposomal Doxorubicin (PLD). Subjects will be treated during each 28-day cycle according to the treatment schedule.

Phase

7.43 miles

Learn More »

Study CB-839 in Combination With Nivolumab in Patients With Melanoma ccRCC and NSCLC

This study is an open-label Phase 1/ 2 evaluation of CB-839 in combination with nivolumab in patients with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer. During Phase 1, patients will be enrolled into escalating dose cohorts to determine the recommended phase 2 dose (RP2D). In Phase ...

Phase

7.43 miles

Learn More »

Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.

Phase

7.43 miles

Learn More »

To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

ABI-007-PST-001 is a Phase 1 / 2, multicenter, open-label, dose-finding study to assess the safety , tolerability, and preliminary efficacy of weekly nab-paclitaxel in pediatric patients with recurrent or refractory solid tumors (excluding brain tumors). The Phase 1 portion of the study, with a dose escalation design, ended and the ...

Phase

7.43 miles

Learn More »

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.

Phase

7.43 miles

Learn More »

DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients

This is a pilot, phase 2, prospective, comparative study to evaluate the safety and efficacy of the combination of Levulan Kerastick for Topical Solution and blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator (LevulanPDT). The study hypothesis is that post solid organ transplantation patients, highly susceptible to ...

Phase

7.7 miles

Learn More »